{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:45Z","timestamp":1788416025376,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the clinical characteristics, risk factors, severity-related factors, and clinical outcomes of immune checkpoint inhibitor-associated pneumonitis (CIP) after immune checkpoint inhibitor (ICI) treatment in elderly patients with lung cancer, providing evidence for risk identification and nursing management during ICI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data from 206 elderly patients with lung cancer who received ICI therapy at the Second Affiliated Hospital of Naval Medical University between March 2024 and February 2026 were retrospectively collected. The incidence, onset time, and Common Terminology Criteria for Adverse Events (CTCAE) grade of CIP were recorded. Univariate and multivariable logistic regression analyses were performed to identify risk factors for CIP. Patients with CIP were classified into mild (grades 1\u20132) and moderate-to-severe (grade \u22653) groups. Clinical characteristics and outcomes were compared between the two groups. Firth penalized logistic regression was used to identify factors associated with CIP severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 206 patients, 33 developed CIP (16.0%). The median time to CIP onset was 58 (45\u201382) days, and 81.8% of cases occurred within 90 days after ICI initiation. Twenty-two patients (66.7%) had mild CIP and 11 (33.3%) had moderate-to-severe CIP. Multivariable logistic regression identified prior thoracic radiotherapy (OR\u00a0=\u00a03.34, 95% CI: 1.45\u20137.69), pulmonary comorbidity (OR\u00a0=\u00a02.94, 95% CI: 1.30\u20136.63), and combination therapy (OR\u00a0=\u00a03.68, 95% CI: 1.36\u201310.00) as independent risk factors for CIP. Firth penalized logistic regression showed that pulmonary comorbidity (OR\u00a0=\u00a08.44, 95% CI: 1.42\u201395.17, P\u00a0=\u00a00.017) and prior thoracic radiotherapy (OR\u00a0=\u00a05.56, 95% CI: 1.07\u201339.63, P\u00a0=\u00a00.041) were associated with moderate-to-severe CIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most CIP cases occurred within the first 3 months after ICI treatment and were mild. Prior thoracic radiotherapy, pulmonary comorbidity, and combination therapy increased the risk of CIP, whereas pulmonary comorbidity and prior thoracic radiotherapy were associated with moderate-to-severe CIP in exploratory analysis. The above findings may provide a reference for the identification of patients with relevant risk factors, early monitoring, and nursing management during ICI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1944973","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:35Z","timestamp":1788413015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors, severity-related factors, and clinical outcomes of immune checkpoint inhibitor-associated pneumonitis in elderly patients with lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score\u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.21037\/tlcr-22-168","article-title":"Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Tao","year":"2022","journal-title":"Trans Lung Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107184","article-title":"Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer\u2013a multicenter observational analysis","volume":"179","author":"Frost","year":"2023","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301931","article-title":"The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small-cell lung cancer: Meta-analyses of controlled clinical trials","volume":"19","author":"Kong","year":"2024","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6244","article-title":"A nomogram model for predicting the risk of checkpoint inhibitor\u2010related pneumonitis for patients with advanced non\u2010small\u2010cell lung cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1607170","article-title":"Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1365966","article-title":"Incidences of pneumonitis associated with the combination of radiotherapy and immune checkpoint inhibitors in lung cancer: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B11","first-page":"28","article-title":"Guidelines for diagnosis and treatment of primary lung cancer (2022 edition)","volume":"19","author":"He","year":"2022","journal-title":"Chin J Ration Drug Use"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad118","article-title":"Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience","volume":"28","author":"Altan","year":"2023","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656063","article-title":"Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13014-025-02617-8","article-title":"Radiation-induced lung injury: from mechanism to prognosis and drug therapy","volume":"20","author":"Wang","year":"2025","journal-title":"Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101711","article-title":"Early immune checkpoint inhibitor administration increases the risk of radiation-induced pneumonitis in patients with stage III unresectable NSCLC undergoing chemoradiotherapy","volume":"17","author":"Qin","year":"2025","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14308","article-title":"Risk factors for pneumonitis in patients with non\u2010small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis","volume":"13","author":"Yamaguchi","year":"2022","journal-title":"Thorac Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13014-024-02489-4","article-title":"Respiratory adverse effects in patients treated with immune checkpoint inhibitors in combination with radiotherapy: a systematic review and meta-analysis","volume":"19","author":"Ma","year":"2024","journal-title":"Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15385","article-title":"Risk factors for severe immune\u2010related pneumonitis after nivolumab plus ipilimumab therapy for non\u2010small cell lung cancer","volume":"15","author":"Sumi","year":"2024","journal-title":"Thorac Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chstcc.2024.100126","article-title":"Managing immune checkpoint inhibitor pneumonitis in the ICU","volume":"3","author":"Montemayor","year":"2025","journal-title":"CHEST Crit Care"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1944973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:36Z","timestamp":1788413016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1944973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1944973"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1944973","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1944973"}}